Summary:
NeoGenomics and Ultima Genomics have partnered to use the UG 100 sequencing platform to advance precision oncology diagnostics through cost-effective, high-accuracy next-generation sequencing.
takeaways:
- NeoGenomics will integrate Ultima’s UG 100 sequencer into its UK innovation center to enhance clinical test development.
- The UG 100 offers high-throughput, low-error, and cost-efficient sequencing ideal for precision oncology applications like liquid biopsy.
- The collaboration supports emerging markets such as minimal residual disease (MRD) detection and whole genome sequencing in cancer care.
NeoGenomics, Inc., a provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance NeoGenomics’ ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation center in Cambridge, UK.
“This collaboration with Ultima, a pioneer in cost-efficient whole genome sequencing, will equip our research and development team with resources to rapidly and efficiently translate innovation for the benefit of patient care,” said Tony Zook, CEO of NeoGenomics. “With precision oncology testing increasingly being based on next generation sequencing, we are continually looking for targeted opportunities to drive innovation that improve patient outcomes.”
UG 100 Cost-Effective and Low-Error
The UG 100 offers a cost-effective and extremely low-error sequencing profile that is a strong fit for NeoGenomics’ emerging clinical assay portfolio that requires large amounts of high-fidelity sequencing data. And with the recent launch of the Solaris portfolio of product advancements, Ultima has now increased sensitivity of variant detection with 5x yield improvements for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA, making the UG 100 a strong fit for applications like liquid biopsy that require finding a “needle-in-the haystack.”
NeoGenomics’ R&D team will use Ultima’s UG 100 to enable development of tests spanning the cancer care continuum.
“We are excited to be working with NeoGenomics, a leader in cancer diagnostics with a strong and established footprint in the oncology ecosystem. With the UG 100, NeoGenomics is well-positioned to explore fast-growing markets in oncology diagnostics such as MRD and emerging whole genome sequencing applications,” said Gilad Almogy, CEO of Ultima Genomics. “Ultima’s. unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications and to excel in applications like liquid biopsy requiring extreme accuracy. For oncology applications, our ppmSeq technology offers accuracy at extremely low limits of detection and at low cost, and we believe will be transformational for applications requiring earlier detection such as MRD.”
Featured Image: Ultima’s UG 100 sequencing platform is being used to advance NeoGenomics’ ability to offer innovative clinical tests. Image: Ultima
